Product Description
Suvecaltamide (also known as JZP385) is a highly selective modulator of T-type calcium channels in development for the potential treatment of moderate to severe essential tremor (ET). T-type calcium channels play a role in the brain's management of muscle movement. (Sourced from: http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-first-patient-enrolled-phase-2b)
Mechanisms of Action: T-Type Calcium Channel
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jazz
Company Location: DUBLIN L2 4
Company CEO: Bruce C. Cozadd
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Poland, Spain, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Essential Tremor|Parkinson's Disease|Tremor
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-001063-27 | P2 |
Active, not recruiting |
Parkinson's Disease |
2025-07-19 |
|
| JZP385-202-01 | P2 |
Unknown Status |
Parkinson's Disease |
2025-03-31 |
|
| 2020-002463-61 | P2 |
Active, not recruiting |
Essential Tremor |
2025-01-08 |
|
| JZP385-202 | P2 |
Recruiting |
Parkinson's Disease|Tremor |
2024-12-31 |
32% |